Editas Medicine, Inc. (EDIT)
Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)
As of Oct 21, 4:00 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow EDIT in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on EDIT and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
EDIT at a glance
Key statistics
$396.24M
Market capitalization
- Previous close
- $2.58
- Open
- $2.59
- Day range
- $2.50 – $2.60
- Volume
- 1.14M
- Average volume (30 sessions)
- 2.97M
- Shares outstanding
- 153.58M
- Earnings per share
- $(0.48)
- Price / book
- 3.8
- Price / sales
- 8.4
- Beta (1 year, vs SPY)
- 2.24
Where the price sits in its year
52-week range
33% of the range
- Below the 52-week high
- -40.4%
- Above the 52-week low
- +51.2%
Completed sessions through Oct 21, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $2.60-3.3%
- 50-day average
- $2.80-10.3%
- 200-day average
- $2.66-5.8%
Between the conventional 30 and 70 bands.
+10.6%
1 week
-14.0%
1 month
-8.1%
3 months
+22.4%
Year to date
-39.4%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with EDIT
EDIT on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on EDIT.
See the plans →
Every planScreen names like EDIT
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on EDIT
Put EDIT on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on EDIT
See whether there is an open premium alert on EDIT, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
EDIT headlines
- Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
GlobeNewswire Inc. · Sep 8, 2026
- Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
GlobeNewswire Inc. · Mar 9, 2026
- Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
GlobeNewswire Inc. · Jun 12, 2025
- Editas Medicine to Participate in Upcoming Investor Conferences
GlobeNewswire Inc. · Aug 28, 2024
- Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
GlobeNewswire Inc. · Jun 14, 2024
- Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
GlobeNewswire Inc. · Jun 14, 2024
- The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
Benzinga · May 30, 2024
- Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
GlobeNewswire Inc. · May 14, 2024
SEC Form 4, most recent first
Insider filings
Ory Daniel Scott
+950.0K
EVP, Chief Medical Officer · Grant or award
· Sep 8, 2026
O'Neill Gilmore Neil
−5.1K
CEO, Director · Open-market sale
$15.56K · Sep 3, 2026
Burkly Linda
−709
EVP, CHIEF SCIENTIFIC OFFICER · Open-market sale
$2.15K · Sep 3, 2026
Parison Amy
−453
SVP, Chief Financial Officer · Open-market sale
$1.38K · Sep 3, 2026
Ellinor Patrick Thomas II
+103.4K
Director · Grant or award
· Aug 6, 2026
Parison Amy
−678
SVP, Chief Financial Officer · Open-market sale
$1.75K · Aug 3, 2026
Burkly Linda
−4.9K
EVP, CHIEF SCIENTIFIC OFFICER · Open-market sale
$13.16K · Jul 28, 2026
Connaughton Bernadette
+51.7K
Director · Grant or award
· Jun 17, 2026
About Editas Medicine, Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Biological Products, (no Diagnostic Substances)
- Headquarters
- Cambridge, MA
- Employees
- 87
- Listed since
- Feb 3, 2016
- Website
- editasmedicine.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.